“In the coming months, we expect potential Phase III readouts for breakwater, which is a very importation for us in BRAF mutated colorectal cancer.”

In context

“line, albeit there are a number of pipeline actions kind of suggested to be initiating too. We are suggesting is as likely as a response to the reset and cost cutting that's going on. My first part to this question is, how will you ensure that this isn't repeated in further quarters? And how are we balancing the need to kind of take stock and cut while ensuring that high potential opportunities are getting appropriately accelerated through the pipeline? Albert Bourla: Then maybe I will ask the 2 R&D heads to comment on that. Please, let's start with Chris. Chris Boshoff: Yes. Thank you for the question. So just to remind us, this year, we've already started 8 new first in-patient studies in oncology, which I believe makes us the number 1 company in terms of Phase I clinical trial started. In the coming months, we expect potential Phase III readouts for breakwater, which is a very importation for us in BRAF mutated colorectal cancer which is up to 10% of colorectal cancer, and that will be in the first line setting, a big unmet need because there's particularly poor prognosis patients presenting with BRAF mutated colorectal cancer. We also expect readouts for Veritex2 our ER [indiscernible] we codeveloping with ovens for ER-positive second-line plus methodic breast cancer and potentially for Crest which is a sasanlimab, a differentiated subcut PD-1 in combination with BCP in non-muscle invasive bladder cancer. We will also present in the coming months, Phase II randomized data for [indiscernible]. This is a randomized Phase II data in patients with prostate cancer. We've seen the data, and that provided us the confidence to initiate the 2 Phase III programs. In the coming months, we'll also start additional Phase III”